During pre-clinical research, a starting lead compound usually requires optimization of one or more of its properties. What is not a property of a lead compound that researchers attempt to optimize?
a) Decreasing the drug's adverse health effects
b) In some diseases, like certain cancers, broaden inhibition of multiple targets"
c) Increase the leads potency at lower concentrations
d) Enhance the drug's distribution to non-target cells in the patient
e) Improving binding specificity of the drug to a target protein